Psych Vivas · Psychopharmacology — metabolic syndrome and psychotropic monitoring
Metabolic syndrome and psychotropic monitoring — consultant viva
Fellowship viva on metabolic criteria, agent hierarchy, monitoring schedule, mechanisms, metformin/switch evidence and special populations.
On this page & tools
Target exams
Station structure
Time: 8–10 minutes. Depth: consultant teaching registrar. Expect named criteria, hierarchy, schedule numbers, and named trials — not vague “monitor physical health”.[1][7]
Core questions and model points
-
Define MetS? Cluster of central obesity/waist, high TG, low HDL, raised BP, raised fasting glucose; NCEP three-of-five vs IDF waist-required frameworks.[10]
-
Why care in psychiatry? High MetS prevalence in SMI; CVD drives premature mortality; drugs amplify risk; monitoring gaps are system failures.[7][8]
-
Rank agents? Highest: clozapine, olanzapine. High–moderate: quetiapine. Intermediate: risperidone/paliperidone. Lower weight: aripiprazole, ziprasidone, lurasidone (relative).[2][7]
-
Mechanisms? H1/5-HT2C appetite; insulin resistance; atherogenic lipids; lifestyle multipliers.[7]
-
ADA/APA schedule? Baseline package; weight 4/8/12 weeks then quarterly; glucose/lipids/BP structured rechecks; act earlier if trajectory bad.[1]
-
Youth? Correll 2009 — large early cardiometabolic shifts with first SGA exposure; denser early monitoring.[4]
-
CATIE pearl? Effectiveness vs metabolic trade-offs; olanzapine not “free” efficacy.[3]
-
Interventions? Lifestyle from day 0; switch when possible (e.g. to aripiprazole); metformin evidence (Wu; Jarskog); treat BP/lipids/diabetes to target.[5][6][9]
-
Metformin teaching dose? Start ~500 mg oral with food, titrate toward 1–2 g/day if eGFR allows; contraindications; adjunct not replacement for choice/monitoring.[5][6]
-
Clozapine exception? Unique TRS efficacy → intensive metabolic management rather than casual cessation.[7][6]
-
Ownership? Psychiatrist owns the plan and escalation even when GP draws bloods; written shared-care checklist.[1][7]
Distinctions that score
Score by separating ranking vs absolute need to monitor, using early weight trajectory as an action trigger, naming Wu/Jarskog for metformin, and refusing both metabolic nihilism (“ignore the labs”) and psychiatric nihilism (“stop all antipsychotics”).[1][5][6][7]
References
- [1]American Diabetes Association, American Psychiatric Association, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care, 2004.PMID 14747245
- [2]Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry, 1999.PMID 10553730
- [3]Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med, 2005.PMID 16172203
- [4]Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA, 2009.PMID 19861668
- [5]Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial JAMA, 2008.PMID 18182600
- [6]Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder Am J Psychiatry, 2013.PMID 23846733
- [7]De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nat Rev Endocrinol, 2011.PMID 22009159
- [8]Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis Schizophr Bull, 2013.PMID 22207632
- [9]Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine J Clin Psychiatry, 2008.PMID 18605811
- [10]Alberti KG, Zimmet P, Shaw J Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation Diabet Med, 2006.PMID 16681555